0XOD Stock Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
UroGen Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.50 |
| 52 Week High | US$24.01 |
| 52 Week Low | US$8.77 |
| Beta | 1.08 |
| 1 Month Change | -14.23% |
| 3 Month Change | -11.48% |
| 1 Year Change | 11.69% |
| 3 Year Change | -24.62% |
| 5 Year Change | n/a |
| Change since IPO | -67.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0XOD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -9.2% | -1.9% | -0.9% |
| 1Y | 11.7% | -30.5% | -1.8% |
Return vs Industry: 0XOD exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0XOD exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0XOD volatility | |
|---|---|
| 0XOD Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0XOD's share price has been volatile over the past 3 months.
Volatility Over Time: 0XOD's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 200 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
UroGen Pharma Ltd. Fundamentals Summary
| 0XOD fundamental statistics | |
|---|---|
| Market cap | US$490.33m |
| Earnings (TTM) | -US$102.24m |
| Revenue (TTM) | US$82.71m |
5.9x
P/S Ratio-4.8x
P/E RatioIs 0XOD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0XOD income statement (TTM) | |
|---|---|
| Revenue | US$82.71m |
| Cost of Revenue | US$9.36m |
| Gross Profit | US$73.35m |
| Other Expenses | US$175.60m |
| Earnings | -US$102.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 88.68% |
| Net Profit Margin | -123.61% |
| Debt/Equity Ratio | -151.1% |
How did 0XOD perform over the long term?
See historical performance and comparison